FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2894596467> ?p ?o ?g. }

• W2894596467 endingPage "486" @default.
• W2894596467 startingPage "478" @default.
• W2894596467 abstract "Abstract Purpose: The presence of hypoxia in the diseased bone marrow presents a new therapeutic target for multiple myeloma. Evofosfamide (formerly TH-302) is a 2-nitroimidazole prodrug of the DNA alkylator, bromo-isophosphoramide mustard, which is selectively activated under hypoxia. This trial was designed as a phase I/II study investigating evofosfamide in combination with dexamethasone, and in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. Patients and Methods: Fifty-nine patients initiated therapy, 31 received the combination of evofosfamide and dexamethasone, and 28 received the combination of evofosfamide, bortezomib, and dexamethasone. Patients were heavily pretreated with a median number of prior therapies of 7 (range: 2–15). All had previously received bortezomib and immunomodulators. The MTD, treatment toxicity, and efficacy were determined. Results: The MTD was established at 340 mg/m2 evofosfamide + dexamethasone with dose-limiting mucositis at higher doses. For the combination of evofosfamide, bortezomib, and dexamethasone, no patient had a dose-limiting toxicity (DLT) and the recommended phase II dose was established at 340 mg/m2. The most common ≥grade 3 adverse events (AE) were thrombocytopenia (25 patients), anemia (24 patients), neutropenia (15 patients), and leukopenia (9 patients). Skin toxicity was reported in 42 (71%) patients. Responses included 1 very good partial response (VGPR), 3 partial response (PR), 2 minor response (MR), 20 stable disease (SD), and 4 progressive disease (PD) for evofosfamide + dexamethasone and 1 complete response (CR), 2 PR, 1 MR, 18 SD, and 5 PD for evofosfamide + bortezomib + dexamethasone. Disease stabilization was observed in over 80% and this was reflective of the prolonged overall survival of 11.2 months. Conclusions: Evofosfamide can be administered at 340 mg/m2 twice a week with or without bortezomib. Clinical activity has been noted in patients with heavily pretreated relapsed refractory multiple myeloma." @default.
• W2894596467 created "2018-10-12" @default.
• W2894596467 creator A5000301432 @default.
• W2894596467 creator A5009765944 @default.
• W2894596467 creator A5012653817 @default.
• W2894596467 creator A5013208787 @default.
• W2894596467 creator A5013730238 @default.
• W2894596467 creator A5014871120 @default.
• W2894596467 creator A5023152679 @default.
• W2894596467 creator A5026014651 @default.
• W2894596467 creator A5027328800 @default.
• W2894596467 creator A5032324034 @default.
• W2894596467 creator A5032464400 @default.
• W2894596467 creator A5039836090 @default.
• W2894596467 creator A5042967384 @default.
• W2894596467 creator A5043526996 @default.
• W2894596467 creator A5049711954 @default.
• W2894596467 creator A5051601274 @default.
• W2894596467 creator A5052048627 @default.
• W2894596467 creator A5053410437 @default.
• W2894596467 creator A5053572690 @default.
• W2894596467 creator A5054346063 @default.
• W2894596467 creator A5055089118 @default.
• W2894596467 creator A5075607061 @default.
• W2894596467 creator A5079336243 @default.
• W2894596467 creator A5081041356 @default.
• W2894596467 date "2019-01-15" @default.
• W2894596467 modified "2023-10-18" @default.
• W2894596467 title "A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma" @default.
• W2894596467 cites W1977328011 @default.
• W2894596467 cites W1992407986 @default.
• W2894596467 cites W2002355437 @default.
• W2894596467 cites W2004575520 @default.
• W2894596467 cites W2010552629 @default.
• W2894596467 cites W2028444391 @default.
• W2894596467 cites W2029206767 @default.
• W2894596467 cites W2033278321 @default.
• W2894596467 cites W2034072253 @default.
• W2894596467 cites W2035779363 @default.
• W2894596467 cites W2044436186 @default.
• W2894596467 cites W2050517391 @default.
• W2894596467 cites W2057895959 @default.
• W2894596467 cites W2067680442 @default.
• W2894596467 cites W2068353461 @default.
• W2894596467 cites W2072972860 @default.
• W2894596467 cites W2087565365 @default.
• W2894596467 cites W2104928951 @default.
• W2894596467 cites W2117692326 @default.
• W2894596467 cites W2119955812 @default.
• W2894596467 cites W2126669622 @default.
• W2894596467 cites W2140579395 @default.
• W2894596467 cites W2143860717 @default.
• W2894596467 cites W2144728882 @default.
• W2894596467 cites W2160486862 @default.
• W2894596467 cites W2162527266 @default.
• W2894596467 cites W2167270217 @default.
• W2894596467 cites W2171427413 @default.
• W2894596467 cites W2201190784 @default.
• W2894596467 cites W2240609751 @default.
• W2894596467 cites W2293214575 @default.
• W2894596467 cites W2343386476 @default.
• W2894596467 cites W2486629951 @default.
• W2894596467 cites W2511571730 @default.
• W2894596467 cites W2528329272 @default.
• W2894596467 cites W2781388087 @default.
• W2894596467 cites W2781873664 @default.
• W2894596467 cites W2783782130 @default.
• W2894596467 cites W2913073599 @default.
• W2894596467 doi "https://doi.org/10.1158/1078-0432.ccr-18-1325" @default.
• W2894596467 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6335171" @default.
• W2894596467 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30279233" @default.
• W2894596467 hasPublicationYear "2019" @default.
• W2894596467 type Work @default.
• W2894596467 sameAs 2894596467 @default.
• W2894596467 citedByCount "27" @default.
• W2894596467 countsByYear W28945964672019 @default.
• W2894596467 countsByYear W28945964672020 @default.
• W2894596467 countsByYear W28945964672021 @default.
• W2894596467 countsByYear W28945964672022 @default.
• W2894596467 countsByYear W28945964672023 @default.
• W2894596467 crossrefType "journal-article" @default.
• W2894596467 hasAuthorship W2894596467A5000301432 @default.
• W2894596467 hasAuthorship W2894596467A5009765944 @default.
• W2894596467 hasAuthorship W2894596467A5012653817 @default.
• W2894596467 hasAuthorship W2894596467A5013208787 @default.
• W2894596467 hasAuthorship W2894596467A5013730238 @default.
• W2894596467 hasAuthorship W2894596467A5014871120 @default.
• W2894596467 hasAuthorship W2894596467A5023152679 @default.
• W2894596467 hasAuthorship W2894596467A5026014651 @default.
• W2894596467 hasAuthorship W2894596467A5027328800 @default.
• W2894596467 hasAuthorship W2894596467A5032324034 @default.
• W2894596467 hasAuthorship W2894596467A5032464400 @default.
• W2894596467 hasAuthorship W2894596467A5039836090 @default.
• W2894596467 hasAuthorship W2894596467A5042967384 @default.
• W2894596467 hasAuthorship W2894596467A5043526996 @default.
• W2894596467 hasAuthorship W2894596467A5049711954 @default.
• W2894596467 hasAuthorship W2894596467A5051601274 @default.
• W2894596467 hasAuthorship W2894596467A5052048627 @default.

• next